Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2005-12-13
2005-12-13
Ketter, James (Department: 1636)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C514S04400A, C424S009200
Reexamination Certificate
active
06974867
ABSTRACT:
Inhibitors of KIAA0175 are provided that reduce the expression or biological activities of KIAA0175, p53 and/or p21 in a mammalian cell. KIAA0175 inhibitors include anti-sense molecules, ribozymes, antibodies and antibody fragments, proteins and polypeptides as well as small molecules. KIAA0175 inhibitors find use in compositions and methods for decreasing KIAA0175, p53 and/or p21 gene expression as well as methods for increasing the chemo and/or radiosensitivity of mammalian cells, including tumor cells, methods for decreasing the side effects of cancer therapy and methods for treating neoplastic diseases.
REFERENCES:
patent: 5700637 (1997-12-01), Southern
patent: 6087485 (2000-07-01), Brooks-Wilson et al.
patent: WO 98/06437 (1998-02-01), None
patent: WO 99/08711 (1999-02-01), None
patent: WO99/65928 (1999-12-01), None
patent: WO 01/16306 (2001-03-01), None
Anderson, F. Human gene therapy. Nature 392:26-30, 1998.
Verma et al. Gene therapy-promises, problems and prospects. Nature 389: 239-242, 1997.
Mountain, A. Gene therapy: first decade. TIBTECH 18: 119-128, 2000.
Branch, A. A good antisense molecule is hard to find. TIBS 23: 45-50, 1998.
Jen K, et al. Suppression of gene expression by targeted disruption of messenger RNA: available options and current strategies. Stem Cells 18: 307-319, 2000.
Banin et al., “Enhanced Phosphorylation of p53 by ATM in Response to DNA Damage,”Science 281(5383):1674-1677, Sep. 11, 1998.
Boulton et al., “Wortmannin is a Potent Inhibitor of DNA Double Strand Break but not Single Strand Break Repair in Chinese Hamster Ovary Cells,”Carcinogenesis(Lond.)17(11):2285-2290, Nov. 1996.
Canman et. al., “Activation of the ATM Kinase by Ionizing Radiation and Phosphorylation of p53,”Science 281(5383):1677-1679, Sep. 11, 1998.
Chen et al., “Identification of Ataxia Telangiectasia Heterozygotes, a Cancer Prone Population,”Nature 274(5670):484-486, Aug. 3, 1978.
Chernikova et al., “Wortmannin Sensitizes Mammalian Cells to Radiation by Inhibiting the DNA-dependent Protein Kinase-Mediated Rejoining of Double-strand Breaks,”Radiation Research 151(2):159-166, Feb. 1999.
Cox et al., “Tumour Suppressors, Kinases and Clamps: how p53 Regulates the Cell Cycle in Response to DNA Damage,”Bioessays 17(6):501-508, Jun. 1995.
El-Deiry “Regulation of p53 Downstream Genes,”Seminars in Cancer Biology 8(5):345-357, 1998.
Elledge et al., “A Question of Balance: The Role of Cyclin-Kinase Inhibitors in Development and Tumorigenesis,”Trends in Cell Biology 6:388-393, Oct. 1996.
Fiscella et al., “Mutation of the Serine 15 Phosphorylation Site of Human p53 Reduces the Ability of p53 to Inhibit Cell Cycle Progression,”Oncogene 8(6):1519-1528, Jun. 1993.
Haupt et al., “Mdm2 Promotes the Rapid Degradation of p53,”Nature 387(6630):296-299, May 15, 1997.
Hendry et al., “P53 Deficiency Produces Fewer Regenerating Spermatogenic Tubules after Irradiation,”International J. of Radiation Biology 70(6):677-682, Dec. 1996.
Hosoi et al., “A Phosphatidylinositol 3-Kinase Inhibitor Wortmannin Induces Radioresistant DNA Synthesis and Sensitizes Cells to Bleomycin and Ionizing Radiation,”International J. of Cancer 78(5):642-647, Nov. 23, 1998.
Huang et al., “Lipitoids—novel Cationic Lipids for Cellular Delivery of Plasmid DNA in vitro,”Chemistry&Biology 5(6):345-354, Jun. 1998.
Kastan et al., “A Mammalian Cell Cycle Checkpoint Pathway Utilizing p53 and GADD45 is Defective in Ataxia-Telangiectasia,”Cell 71(4):587-597, Nov. 13, 1992.
Keith et al., “PIK-related Kinases: DNA Repair, Recombination, and Cell Cycle Checkpoints,”Science 270(5233):50-51, Oct. 6, 1995.
Kim et al., “Substrate Specificities and Identification of Putative Substrates of ATM Kinase Family Members,”J. Biol. Chem. 274(53):37538-37543, Dec. 31, 1999.
Komarova et al., “Could p53 be a Target for Therapeutic Suppression?,”Semin. Cancer Biol. 8(5):389-400, 1998.
Komarova et al., “Transgenic Mice with p53-Responsive lacZ: p53 Activity Varies Dramatically During Normal Development and Determines Radiation and Drug Sensitivity in vivo,”EMBO J. 16(6):1391-1400, 1997.
Kubbutat et al., “Regulation of Mdm2-directed Degradation by the C Terminus of p53,”Molecular and Cellular Biology 18(10):5690-5698, Oct. 1998.
Kubbutat et al., “Regulation of p53 Stability by Mdm2,”Nature 387(6630):299-303, May 15, 1997.
Lehmann et al., “Miscellaneous Observations on DNA Repair in Ataxia-Telangiectasia,” in Bridges and Harnden (eds.),Ataxia-Telangiectasia—A Cellular and Molecular Link Between Cancer, Neurophathology and Immune Deficiency, John Wiley and Sons, New York, 1982, pp. 347-353.
Lowe et al., “p53-Dependent Apoptosis Modulates the Cytotoxicity of Anticancer Agents,”Cell 74(6):957-967, Sep. 24, 1993.
Lu et al., “Differential Induction of Transcriptionally Active p53 Following UV or Ionizing Radiation: Defects in Chromosome Instability Syndromes?,”Cell 75(4):765-778, Nov. 19, 1993.
Matsuoka et al., “Linkage of ATM to Cell Cycle Regulation by the Chk2 Protein Kinase,”Science 282(5395):1893-1897, Dec. 4, 1998.
Momand et al., “The mdm-2 Oncogene Product Forms a Complex with the p53 Protein and Inhibits p53-Mediated Transactivation,”Cell 69(7):1237-1245, Jun. 26, 1992.
Nagase et al., “Prediction of the Coding Sequences of Unidentified Human Genes. V. The Coding Sequences of 40 New Genes (KIAA0161-KIAA0200) Deduced by Analysis of cDNA Clones from Human Cell Line KG-1,”DNA Research 3(1):17-24, Feb. 29, 1996.
Oliner et al., “Oncoprotein MDM2 Conceals the Activation Domain of Tumour Suppressor p53,”Nature 362(6423):857-860, Apr. 29, 1993.
Powis et al., “Wortmannin, a Potent and Selective Inhibitor of Phosphatidylinositol-3-Kinase,”Cancer Research 54(9):2419-2423, May 1, 1994.
Price et al., “The Phosphatidylinositol 3-Kinase Inhibitor Wortmannin Sensitizes Murine Fibroblasts and Human Tumor Cells to Radiation and Blocks Induction of p53 Following DNA Damage,”Cancer Research 56(2):246-250, Jan. 15, 1996.
Rogel et al., “p53 Cellular Tumor Antigen: Analysis of mRNA Levels in Normal Adult Tissues, Embryos, and Tumors,”Molecular and Cellular Biology 5(10):2851-2855, Oct. 1985.
Rosenzweig et al., “Radiosensitization of Human Tumor Cells by the Phosphatidylinositol 3-Kinase Inhibitors Wortmannin and LY294002 Correlates with Inhibition of DNA-Dependent Protein Kinase and Prolonged G2-M Delay,”Clinical Cancer Research 3(7):1149-1156, Jul. 1997.
Savitsky et al., “A Single Ataxia Telangiectasia Gene with a Product Similar to PI-3 Kinase,”Science 268(5218):1749-1753, Jun. 23, 1995.
Sarkaria et al., “Inhibition of Phosphoinositide 3-Kinase Related Kinases by the Radiosensitizing Agent Wortmannin,”Cancer Research 58(19):4375-4382, Oct. 1, 1998.
Schmid et al., “Expression of p53 During Mouse Embryogenesis,”Development 113(3):857-865, Nov. 1991.
Schwartz et al., “Expression of p53 Protein in Spermatogenesis is Confined to the Tetraploid Pachytene Primary Spermatocytes,”Oncogene 8(6):1487-1494, Jun. 1993.
Sherr, “Cancer Cell Cycles,”Science 274(5293):1672-1677, Dec. 6, 1996.
Shieh et al., “DNA Damage-Induced Phosphorylation of p53 Alleviates Inhibition by MDM2,”Cell 91(3):325-334, Oct. 31, 1997.
Siliciano et al., “DNA Damage Induces Phosphorylation of the Amino Terminus of p53,”Genes&Development 11:3471-3481, 1997.
Tron et al., “p53-Regulated Apoptosis is Differentiation Dependent in Ultraviolet B-Irradiated Mouse Keratinocytes,”American J. of Pathology 153(2):579-585, Aug. 1998.
Wang et al., “Loss of p21 Increases Sensitivity to Ionizing Radiation and Delays the Onset of Lymphoma in atm-Deficient Mice,”P.N.
Seeley Todd W.
Williams Lewis T.
Wu Bin
Chiron Corporation
Harbin Alisa A.
Ketter James
Lambertson David A.
Potter Jane E. R.
LandOfFree
Compositions and methods for treating neoplastic disease... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treating neoplastic disease..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treating neoplastic disease... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3488067